At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 251 enrolled
Drug / intervention
mavacamten +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
In Brief
A Phase 3 clinical trial evaluating mavacamten and Placebo for Obstructive Hypertrophic Cardiomyopathy. Completed, enrolled 251 participants across 71 sites in 13 countries.
Detailed Summary
This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM). Approximately 220 participants will be randomized to receive placebo or mavacamten.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Hypertrophic Cardiomyopathy
CountriesBelgium, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2018
Primary CompletionMar 2020
Study CompletionMay 2020
TodayJul 2026
First PostedMar 20, 2018
Enrollment StartMay 29, 2018
Primary CompletionMar 14, 2020
Study CompletionMay 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.3 years ago
Interventions
mavacamtendrug
mavacamten capsules
Placebodrug
placebo oral capsule